Biolight Life Sciences Ltd. · TASE:BOLT
Biolight Life Sciences — IPO Roadshow (February 2016)
30 slides from Biolight Life Sciences's IPO roadshow presentation, Feb 26, 2016
Slide 1: Corporate Presentation February 2016
Corporate Presentation February 2016 Issuer Free Writing Prospectus dated February 25 , 2016 Filed Pursuant to Rule 433 Registration Statement No. 333 - 209454
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements This presentation constitutes a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission or retained by Biolight Life Sciences Ltd. (“we”, “us” or “our”) under Rule 433 to the Securities Act of 1933 , as amended, or the A
Slide 3: Free Writing Prospectus Statement
This presentation highlights basic information about us and the offering to which this communication relates. Because it is a summary, it does not contain all of the information that you should consider before investing in our securities . We have filed a registration statement (including a prospect
Slide 4: Offering Summary
4 Offering Summary Issuer: BioLight Life Sciences Ltd. Symbols/Exchange : BOLT/BOLTW (NASDAQ Capital Market ) Offering Size: $ 12 Million Offering: Ordinary Shares and Warrants ( 100 % Primary) Warrants Offered: Each warrant shall have an exercise price equal to 150 % of the public offering price pe
Slide 5: Overview
5 • Emerging global ophthalmic company • Focused on discovery , development and commercialization of products which target ophthalmic conditions including: • Glaucoma • Dry eye syndrome (DES) • Age - related macular degeneration (AMD) • Products are designed to address a number of significant unmet
Slide 6: Corporate and Financial Summary
6 Corporate and Financial Summary • Traded on Tel Aviv Stock Exchange (BOLT) • 2.6 million shares outstanding; 3.5 million fully diluted • Backed by strategic investors with significant life sciences experience • Israel Makov , former President & CEO of Teva Pharma • Dilip Shanghvi , founder and man
Slide 7: Targeting Three Major Ophthalmic Conditions
• Collection of ocular disorders characterized by progressive loss of visual field due to optic nerve damage • U sually involves uncontrolled increase in Inter Ocular Pressure (IOP) • Can lead to progressive, irreversible vision loss and blindness • Chronic disease that requires ongoing, lifelong tr
Slide 8: Addressing Several Significant Unmet Medical Needs
• Lack of objective, quantitative or semi - quantitative tests to: • Accurately detect DES / identify its causes • Assist in generating personalized therapy • M onitor the effectiveness of selected therapy • Non - compliance with prescribed administration of eye drops • Safer and more precise altern
Slide 9: Our Strategy
Developing and expanding a balanced and diverse pipeline of ophthalmic products and product candidates Maintaining a global, diverse network of ophthalmic specialists to accelerate knowledge synergies and innovation Establishing a sales force to maximize the commercial potential of our products Targ
Slide 10: Eye-D
wo BIOLIGHT Cire Sciences Lea
Slide 11: Compliance is Key for Treatment Efficacy
Approximately 50 % of glaucoma patients may be non - compliant with their drug therapy administration Compliance is Key for Treatment Efficacy 11
Slide 12: Our Solution: Eye-D
12 Our Solution: Eye - D TM • Platform technology that enables a controlled release of ophthalmic medications over time through a subconjunctival insert • First product candidate (VS - 101 ), contains latanoprost, the most prescribed glaucoma medication worldwide • Safe and simple in - office proced
Slide 13: Eye-D VS-101 Market Opportunity
13 Global glaucoma pharmaceutical market is expected to increase from approximately $ 4.7 billion in 2015 to nearly $ 6.1 billion in 2020 The most robust growth in glaucoma pharmaceutical sales is expected to occur in the emerging markets of China, India and Latin America Nearly 75 % of the patients
Slide 14: IOPtiMate
lOPtiMate” es i are a iy F#BIOLIGHT =, i
Slide 15: Laser is a Magic Word in Ophthalmology
15 Laser is a Magic Word in Ophthalmology Refractive 1983 Ǧ Excimer Glaucoma 2015 - IOPtiMate TM Cataract 2009 - Laser Capsulotomy
Slide 16: The IOPtiMate System: Transforming Glaucoma Surgery
16 Novel surgical system that enables a non - penetrating, CO 2 laser - assisted procedure known as CLASS (CO 2 Laser - Assisted Sclerotomy Surgery) to reduce elevated IOP CLASS is an automated, easy to perform procedure which requires only a short learning curve and provides a safer and more precis
Slide 17: Worldwide Clinical Results Demonstrate High Efficacy & Safety
17 Worldwide Clinical Results Demonstrate High Efficacy & Safety Source: Am J Ophthalmol. 2009 Nov; 148 ( 5 ): 670 - 84 ; 2009 Aug 11 ; Three - year follow - up of the tube versus trabeculectomy study ; Gedde SJ, American Journal of Ophthalmology ( 2007 ) Volume: 143 , Issue: 1 , Pages: 23 - 31 ; Su
Slide 18: Worldwide Clinical Results Demonstrate High Efficacy & Safety
18 Worldwide Clinical Results Demonstrate High Efficacy & Safety Performed on 111 patients in 9 sites with 5 - years follow up Source: Am J Ophthalmol. 2009 Nov; 148 ( 5 ): 670 - 84 ; 2009 Aug 11 ; Three - year follow - up of the tube versus trabeculectomy study ; Gedde SJ, American Journal of Ophth
Slide 19: IOPtiMate System Market Opportunity
19 Designed to enable a wider range of ophthalmic surgeons to perform glaucoma surgeries Has the potential to replace existing glaucoma medical procedures driving an increase in the quantity and quality of glaucoma surgeries worldwide Currently b eing marketed primarily in Asia (mainly China, the wo
Slide 20: TeaRx
TeaRx”" BRIO) os
Slide 21: Current DES Diagnosis Paradigm is Lacking
Current DES Diagnosis Paradigm is Lacking • DES is a complex syndrome • Various pathophysiologies • Common clinical pathway • Many therapeutic development failures • Patient selection? • Sub - grouping with limited diagnostic tools? • Current diagnostic tools are confined to single parameter testing
Slide 22: TeaRx: Breakthrough Diagnosis Solution for DES
Enables in - office diagnosis , companion diagnostics and monitoring of DES therapy + drug development/research applications 22 Multi - assay, objective, semi - quantitative analysis of tear film in order to identify one or more underlying causes of DES TeaRx TM : Breakthrough Diagnosis Solution for
Slide 23: TeaRx: Positive Clinical Trials Results
• First human clinical trial in the U.S . ~ 200 subjects • Significant correlation between TeaRx TM ’s assays and the existing benchmark tests • Second human clinical trial in the U.S. assessed the effectiveness of the TeaRx TM test in evaluating tears of healthy subjects as well as of patients suff
Slide 24: TeaRx Market Opportunity
Strong demand for personalized treatment and companion diagnostics solutions Current tests cannot determine cause(s) of this multi - factorial syndrome More than 100 million people are effected by DES worldwide, of whom 20 - 40 million are in the U.S. 24 Diagnostics Treatment One of the leading caus
Slide 25: OphRx LLC
OphRx LLC = i are S iy F#BIOLIGHT ., =, i
Slide 26: OphRx LLC Technology Platform
An alternative solution to current ocular drug delivery modalities Drug delivery using eye drops for both front and back of the eye OphRx LLC Technology Platform 26 Changing the Current Interavitreal Injections Administration To Eye Drops Administration
Slide 27: OphRx LLC Drug Delivery Technology Platform
27 • Technology designed for improved molecule transport across membranes • Unique crystal liquids structure allows loading of different kind of molecules and their release in different target areas • Results of an initial preclinical study showed that the delivery platform enables more efficient an
Slide 28: OphRx LLC Market Opportunity
AMD affects 30 to 50 million people worldwide, of whom 15 million are in the U.S . Only 1 drug currently has FDA approval with limited efficacy and tolerability DES affects more than 100 million people worldwide , of whom 20 - 40 million in the U.S. 600,000 new cases diagnosed globally each year, of
Slide 29: Current Portfolio Status
29 Current Portfolio Status IOPtiMate TM • Regulatory approvals in Europe, China, Canada, Peru, Mexico and Israel. Additional regulatory approvals expected in 2016. • First sales in HK, Hungary, Romania, Poland, Peru and Portugal • Additional distribution agreements and regulatory approvals in selec
Slide 30: In Summary
Multiple Opportunities in High - Growth Markets Innovative Business Model Strong Leadership Team 30 Notable combination of world - renowned key shareholders and experienced management team as well as a network of ophthalmic specialists Our pipeline addresses a number of significant unmet medical nee
BioLight Life Sciences — IPO Roadshow (February 2016) on 6ix